Conjugated Linoleic Acid (CLA) for Cardiovascular Disease

Verdict: CLA does not help heart health

Conjugated linoleic acid (CLA) supplements do not improve cardiovascular health, and higher doses carry safety signals (oxidative stress, inflammation, worse blood sugar). They should not be taken to protect the heart.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This earns a D (Counter-Evidence) grade because high-quality trials consistently show no benefit on the markers that matter. A 2024 GRADE dose-response meta-analysis (PMID 39439191, 14 RCTs) found no significant effect on blood lipids or blood pressure, and a 2022 meta-analysis of lipid profiles (PMID 36438733, 56 RCTs) confirmed no change in triglycerides, total cholesterol, or LDL, with HDL ('good') cholesterol nudging slightly downward. A separate review of blood pressure and endothelial function (PMID 35940238) likewise found no meaningful improvement.

More concerning, the evidence points the wrong way on safety. A 2023 GRADE meta-analysis in people at cardiovascular risk (PMID 37794481) reported higher fasting glucose and a rise in the liver enzyme AST, and a landmark 2002 RCT (PMID 12370214) showed the t10,c12 isomer sharply increased oxidative stress and C-reactive protein, linking CLA to worse insulin resistance. No trial has ever tested CLA against hard outcomes like heart attack or stroke.

Regulators reinforce this picture. The EU's EFSA rejected CLA's body-fat claim, noting it raised lipid peroxidation and inflammation markers, and the WHO now classifies CLA as a trans fat subject to a strict intake limit. The US FDA's clearance is a food-safety (GRAS) status only and endorses no heart benefit; NIH ODS flags caution, while major cardiology bodies do not recommend it.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.32

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

D · Counter-Evidence

Confidence

75%

Broadly consistent

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L2 PubMedPrimary literature

0.20

L3 MechanismPlausibility

0.25

L1 ExamineGlobal benchmark

0.30

L11 AI re-checkIndependent read

0.30

L5 Clinical bodiesAuthoritative stance

0.55

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.32
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Effects of conjugated linoleic acid supplementation on cardiovascular risk factors in patients at risk of cardiovascular disease: a GRADE-assessed systematic review and dose-response meta-analysis

PMID: 39439191 2024 統合分析

Finding: In 14 RCTs of at-CVD-risk patients, CLA produced small anthropometric reductions (body weight -0.72 kg [95% CI -1.11, -0.33], BMI -0.22 kg/m^2 [-0.44, -0.00], body-fat -1.32% [-2.24, -0.40]) but NO significant effect on any lipid-profile marker and NO significant effect on SBP/DBP; authors conclude the effects 'may not reach clinical importance'.

🟢 High quality Effect size: Body weight WMD -0.72 kg (95% CI -1.11 to -0.33, p<0.001); BMI WMD -0.22 kg/m^2 (-0.44 to -0.00, p=0.037); body-fat -1.32% (-2.24 to -0.40, p=0.005); lipid profile and BP: NS

View on PubMed

Effects of CLA supplementation on glycemic control, adipokines, cytokines, MDA and liver enzymes in patients at risk of CVD: a GRADE-assessed dose-response meta-analysis

PMID: 37794481 2023 統合分析

Finding: In 13 RCTs of at-CVD-risk patients, CLA significantly INCREASED fasting blood glucose by +4.49 mg/dL (95% CI 2.39, 6.59; p<0.001) and AST by +2.54 IU/L (95% CI 0.06, 5.01; p=0.044); modest decreases in IL-6 (-0.44 pg/mL) and leptin (-1.69 ng/mL) were observed; HbA1c, MDA, ALT, TNF-alpha, adiponectin: NS — i.e. a small but consistent ADVERSE metabolic signal on glucose and liver enzymes.

🟢 High quality Effect size: FBG WMD +4.49 mg/dL (95% CI +2.39 to +6.59, p<0.001); AST WMD +2.54 IU/L (95% CI +0.06 to +5.01, p=0.044); IL-6 WMD -0.44 pg/mL (-0.86 to -0.02, p=0.037); leptin WMD -1.69 ng/mL (-1.80 to -1.58, p<0.001)

View on PubMed

Effects of conjugated linoleic acid supplementation on blood pressure and endothelial function in adults: A systematic review and dose-response meta-analysis

PMID: 35940238 2022 統合分析

Finding: In 18 RCTs, CLA did NOT change SBP (WMD -0.48 mmHg, 95% CI -3.23 to +2.27) or DBP (WMD -0.71 mmHg, 95% CI -3.54 to +2.12); ICAM was significantly reduced (WMD -8.02, 95% CI -13.95 to -2.09) but VCAM was unchanged — a partial endothelial-marker signal of unclear clinical relevance, no BP benefit.

Effect size: SBP WMD -0.48 mmHg (NS); DBP WMD -0.71 mmHg (NS); ICAM WMD -8.02 (95% CI -13.95 to -2.09, significant); VCAM WMD -34.02 (NS)

View on PubMed

Effects of conjugated linoleic acid supplementation on lipid profile in adults: A systematic review and dose-response meta-analysis

PMID: 36438733 2022 統合分析

Finding: Across 56 RCTs with 73 effect sizes, CLA produced NO significant change in triglycerides (WMD +1.76), total cholesterol (+0.86), LDL-C (+0.49), ApoA, or ApoB; HDL-C was SLIGHTLY but significantly LOWERED (WMD -0.40 mg/dL, 95% CI -0.72 to -0.07) — direction is unfavourable, magnitude clinically trivial. Confirms CLA has no meaningful lipid-modifying effect.

🟢 High quality Effect size: TG WMD +1.76 (NS); TC WMD +0.86 (NS); LDL-C WMD +0.49 (NS); HDL-C WMD -0.40 mg/dL (95% CI -0.72 to -0.07, p<0.05, direction adverse but trivial); ApoA -3.15 (NS); ApoB -0.73 (NS)

View on PubMed

Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance (Risérus et al.)

PMID: 12370214 2002 RCT (double-blind) n = 60

Finding: Purified t10,c12-CLA markedly increased 8-iso-PGF2alpha by +578% (p<0.0001) and C-reactive protein by +110% (p<0.01) vs placebo in men with metabolic syndrome; oxidative-stress increase correlated INDEPENDENTLY with worsened insulin resistance, independent of changes in glycaemia or dyslipidaemia — landmark isomer-specific safety signal cited by every later CLA safety review.

Academic Effect size: t10,c12 vs placebo: 8-iso-PGF2alpha +578% (p<0.0001); CRP +110% (p<0.01); isomer-specific (c9,t11 arm milder)

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Supportive

FDA has no questions. The notice concerns conjugated linoleic acid isomers intended for use as an ingredient in certain specified foods within the general categories of soy milk, meal replacement beverages and bars, milk products and fruit juices at levels up to 3 grams per serving. source↗

L4b EU EFSA

Against

The Panel considers that the information provided does not establish that a reduction in body fat mass, when accompanied by an increase in markers of lipid peroxidation and inflammation, is a beneficial physiological effect for the target population. source↗

L4d TW TFDA / 衛福部

Neutral

已公告的健康食品規格標準（雙軌制第二軌）目前僅有「魚油」與「紅麴」兩項；其餘成分（包含共軛亞麻油酸 CLA）若欲取得「健康食品（小綠人）」標章，須循第一軌個案審查，提交安全性、功效性、安定性試驗報告，由衛生福利部審查取得「衛部健食字」許可證後方得宣稱13項法定保健功效之一。 source↗

L4e WHO

Cautious

For the purposes of these recommendations, TFA includes all fatty acids with a double bond in the trans configuration, regardless of whether the TFA come from ruminant sources or are produced industrially. [footnote 6:] This definition includes conjugated linoleic acid. source↗

L5a NIH Office of Dietary Supplements

Cautious

L5c Cleveland Clinic

Neutral

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬5 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-conjugated-linoleic-acid-001 繁體中文版 →